首页> 美国卫生研究院文献>Journal of Virology >Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus
【2h】

Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus

机译:在没有辅助腺病毒的情况下生产高滴度重组腺相关病毒载体

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Recently, efficient and long-term in vivo gene transfer by recombinant adeno-associated virus type 2 (rAAV) vectors has been demonstrated in a variety of tissues. Further improvement in vector titer and purity will expedite this in vivo exploration and provide preclinical information required for use in human gene therapy. In an effort to obtain higher titers, we constructed a novel AAV helper plasmid which utilizes translational control of AAV Rep genes (J. Li et al., J. Virol. 71:5236–5243, 1997). To address the issue of purity, in this study we report the first rAAV production method which is completely free of adenovirus (Ad) helper virus. The new production system uses a plasmid construct which contains a mini-Ad genome capable of propagating rAAV in the presence of AAV Rep and Cap genes. This construct is missing some of the early and most of the late Ad genes and is incapable of producing infectious Ad. Transfection of 293 cells with the new mini-Ad helper and AAV packaging plasmids results in high-titer rAAV vectors with yields greater than 1,000 transducing units, or 105 viral particles per cell. When rAAV vectors were produced by using this production scheme and compared to traditional heat-inactivated rAAV preparations in vitro and in vivo, we observed transduction equivalent to or better than normal levels. The complete removal of infectious Ad from AAV production should facilitate a better understanding of immune response to AAV vectors in vivo, eliminate the need for developing replication-competent Ad assays, and provide a more defined reagent for clinical use.
机译:最近,已在各种组织中证明了通过重组腺相关病毒2型(rAAV)载体进行的有效且长期的体内基因转移。载体滴度和纯度的进一步改善将加快这种体内探索,并提供用于人类基因治疗所需的临床前信息。为了获得更高的滴度,我们构建了一种新的AAV辅助质粒,该质粒利用AAV Rep基因的翻译控制(J. Li等,J。Virol。71:5236–5243,1997)。为了解决纯度问题,在这项研究中,我们报告了第一种完全不含腺病毒(Ad)辅助病毒的rAAV生产方法。新的生产系统使用质粒构建体,该构建体包含一个微型Ad基因组,该基因组能够在AAV Rep和Cap基因存在的情况下繁殖rAAV。该构建体缺少一些早期和大多数晚期Ad基因,并且不能产生感染性Ad。用新型mini-Ad辅助和AAV包装质粒转染293细胞可得到高滴度rAAV载体,其产量大于1000个转导单位,或每个细胞10 5 病毒颗粒。当使用此生产方案生产rAAV载体并将其与传统的热灭活rAAV制剂进行体外和体内比较时,我们观察到与正常水平相当或更好的转导。从AAV生产中完全去除感染性Ad应该有助于更好地理解体内对AAV载体的免疫反应,消除对开发具有复制能力的Ad测定的需要,并为临床使用提供更明确的试剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号